SCHEMBL4542873

SCHEMBL4542873

FC(F)(F)CN1CCC1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5314785 0.94 LMNA (0.36)
SCHEMBL196492 0.91 HRH3 (0.39)
SCHEMBL3316329 0.91 HRH3 (0.39)
Hydrochloric Acid SCHEMBL25233214 0.88 ALDH1A1 (0.38)
SCHEMBL25235628 0.87 KDM1A (0.34)
SCHEMBL12617201 0.85 TSHR (0.36)
Hydrochloric Acid SCHEMBL25234812 0.84 KDM1A (0.33)
SCHEMBL30341319 0.84 KDM4E (0.31)
SCHEMBL2606082 0.83 KDM4E (0.46)
SCHEMBL12337635 0.80

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260070879-A1 ISOXAZOLINE DERIVATIVES ELANCO TIERGESUNDHEIT AG (CH) 2026-03-12 US claimed
US-11524968-B2 Heterocyclic compound as a protein kinase inhibitor HK INNO.N CORPORATION (KR) 2022-12-13 US claimed
CN-114656485-A Preparation method of trifluoroethyl-containing azetidine derivative 浙江师范大学 2022-06-24 CN claimed
CN-113200999-A Derivative containing trifluoroethyl azetidine and preparation method thereof 浙江师范大学 2021-08-03 CN claimed
US-20260132109-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY NOVARTIS PHARMA AG (CH) 2026-05-14 US disclosed
US-12503436-B2 Compounds and compositions for treating conditions associated with STING activity NOVARTIS PHARMA AG (CH) 2025-12-23 US disclosed
US-12221436-B2 Anthranilamides, their use as insecticide and processes for preparing the same PI INDUSTRIES LTD. (IN) 2025-02-11 US disclosed
US-20240109903-A1 SUBSTITUTED HETEROCYCLES FOR TREATING CANCER NORTHWESTERN UNIVERSITY 2024-04-04 US disclosed
US-11919915-B2 Compounds and methods useful for stabilizing phenylalanine hydroxylase mutations AGIOS PHARMACEUTICALS, INC. (US) 2024-03-05 US disclosed
US-20230339980-A1 COMPOUNDS AND METHODS USEFUL FOR STABILIZING PHENYLALANINE HYDROXYLASE MUTATIONS AGIOS PHARMACEUTICALS, INC. (US) 2023-10-26 US disclosed
US-20230250106-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY NOVARTIS PHARMA AG (CH) 2023-08-10 US disclosed
US-20230167057-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY NOVARTIS PHARMA AG (CH) 2023-06-01 US disclosed
CN-113200999-A Derivative containing trifluoroethyl azetidine and preparation method thereof 浙江师范大学 2021-08-03 CN disclosed
CN-113200999-A Derivative containing trifluoroethyl azetidine and preparation method thereof 浙江师范大学 2021-08-03 CN disclosed
CN-113200999-A Derivative containing trifluoroethyl azetidine and preparation method thereof 浙江师范大学 2021-08-03 CN disclosed
CN-108349946-B Quinoxaline and pyridopyrazine derivatives as PI3K beta inhibitors 詹森药业有限公司 2021-05-18 CN disclosed
CN-107922379-A Substituted guanidine derivatives 宇部兴产株式会社 2018-04-17 CN disclosed
CN-107438603-A Pyrazole compounds and methods of making and using the same 里格尔药品股份有限公司 2017-12-05 CN disclosed
EP-2638031-A1 PYRAZOLE AMINOPYRIMIDINE DERIVATIVES AS LRRK2 MODULATORS F.HOFFMANN-LA ROCHE AG (CH) 2013-09-18 EP disclosed
WO-2012062783-A1 PYRAZOLE AMINOPYRIMIDINE DERIVATIVES AS LRRK2 MODULATORS F. HOFFMANN-LA ROCHE AG (CH) 2012-05-18 WO disclosed